IMMUNOTHERAPY BRIDGE
December 5, 2015
Maria Libera Ascierto
Kimmel Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland
Alfredo Budillon
Experimental Pharmacology Unit, National Cancer Institute “Fondazione G. Pascale” of Naples, Italy
Filippo de Braud
National Cancer Institute of Milan, Italy
Silvia Formenti
Department of Radiation Oncology, Weill Cornell Medical College, New York
Sacha Gnjatic
Tisch Cancer Institute, Hematology/Oncology, Immunology, Icahn School of Medicine at Mount Sinai, New York
Cesare Gridelli
“S.G. Moscati” Hospital, Avellino, Italy
Hans Joerg Hammers
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
Vera Hirsh
McGill University, Royal Victoria Hospital, Montreal, Canada
Rolf Kiessling
Karolinska Institutet, Stockholm, Sweden
Ignacio Melero
CIMA, CUN and Medical School, University of Navarra, Pamplona, Spain
Rita Nanda
Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, Illinois
Graham Pawelec
Second Deperment of Internal Medicine, University of Tuebingen, Tuebingen, Germany
Sandro Pignata
National Cancer Institute “Fondazione G. Pascale” of Naples, Italy
Pedro Romero
Ludwig Center for Cancer Research, University of Lausanne, Switzerland
Daniel Speiser
Department of Oncology and Ludwig Cancer Research Center, University of Lausanne, Switzerland
* To be confirmed
For information please contact info@melanomabridge.org
